[go: up one dir, main page]

HK1132190B - Liquid preparation for internal use - Google Patents

Liquid preparation for internal use Download PDF

Info

Publication number
HK1132190B
HK1132190B HK09112032.6A HK09112032A HK1132190B HK 1132190 B HK1132190 B HK 1132190B HK 09112032 A HK09112032 A HK 09112032A HK 1132190 B HK1132190 B HK 1132190B
Authority
HK
Hong Kong
Prior art keywords
extract
liquid preparation
acid
swertia
liquid
Prior art date
Application number
HK09112032.6A
Other languages
Chinese (zh)
Other versions
HK1132190A1 (en
Inventor
大塚茂则
山田浩之
冈田实
村田操
金子哲男
今森胜美
Original Assignee
Ss制药株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2001264442A external-priority patent/JP2003073291A/en
Application filed by Ss制药株式会社 filed Critical Ss制药株式会社
Publication of HK1132190A1 publication Critical patent/HK1132190A1/en
Publication of HK1132190B publication Critical patent/HK1132190B/en

Links

Abstract

A liquid preparation internal use which is composed of swertia extracts, pharmaceutical components having effect on the digestive system selected from ginger extract, ginseng extract, tumeric extract, cinnamic oil, eugenol, thymol or carnitine chloride, and remainder of auxiliary ingredients, and is adjusted to pH 4-7. The pharmaceutical activity of the liquid preparation internal use of the present invention continues over a long period of time, because the active ingredients in the swertia extracts are kept stable for a long time.

Description

Liquid preparation for oral administration
The present invention is a divisional application with the title of "liquid oral preparation" on application number 02141424.6, application date 2002, 8/30/h.
Technical Field
The present invention relates to a liquid oral preparation which can stably maintain the active ingredients of swertia japonica Makino extract for a long period of time.
Background
The crude drug Swertia japonica (Swertia Herb) is a whole plant of Swertia japonica Makino in flowering period, is classified as bitter stomachic, and has medicinal effects of treating gastritis, hyperacidity, anorexia, etc. The swertia japonica Makino contains Swertiamarin (Swertiamarin), Swertiamarin, red pelatarin, swertia pseudochinensis, oleanolic acid, and gentisic.
The preparations containing the stomach-invigorating crude drugs such as swertia japonica, etc. have been known from old times as powder preparations, tablets, etc. and in recent years, rapid absorption after administration is expected to result in quick-acting properties, so that liquid oral preparations have been marketed.
However, once swertia japonica Makino is incorporated into a liquid oral preparation, it is found that the content of swertiamarin, which is one of the active ingredients thereof, is decreased with the lapse of time.
It is therefore an object of the present invention to provide a liquid oral preparation which can stably retain swertia japonica Makino extract for a long period of time.
Disclosure of Invention
The present inventors have studied the cause of the decrease in swertia japonica Makino extract content from various viewpoints such as temperature, concentration, and pH, and as a result, have found that: the pH is extremely important for the stability of the swertiamarin content in swertia japonica Makino extract in a liquid preparation over time, and further, if the pH is adjusted to 4 to 7, a liquid internal preparation having excellent stability of the swertiamarin content over time can be obtained, and the present invention has been completed.
That is, the present invention provides a liquid internal preparation containing swertia japonica Makino extract and having a pH adjusted to 4 to 7.
Detailed Description
The liquid oral preparation of the present invention contains swertia japonica Makino extract having a bitter stomach-invigorating component. The swertia japonica Makino extract is obtained by extracting swertia japonica Makino with solvent such as cold water, hot water, ethanol, and water-ethanol mixture, preferably water-ethanol mixture.
The content of swertia japonica Makino extract in the liquid oral preparation of the present invention is 5 to 3000mg in terms of crude drug as 1 daily dose, and particularly preferably 10 to 1500 mg.
The pH of the liquid oral preparation of the present invention is required to be 4 to 7, preferably 4.4 to 6.3, more preferably 4.5 to 6.0, and particularly preferably 4.8 to 5.8, from the viewpoint of stability of the swertiamarin content in swertia japonica Makino extract over time.
When the pH is adjusted to 4 to 7, a buffer having a pH in this range is suitably used, and examples of the buffer include buffers containing citric acid, succinic acid, acetic acid, tartaric acid, hydrochloric acid, sulfuric acid, gluconic acid, lactic acid, fumaric acid, boric acid, maleic acid, phosphoric acid, methanesulfonic acid, malic acid, salts thereof, and the like, and among them, citric acid, sodium citrate, tartaric acid, sodium tartrate, malic acid, sodium malate, and the like are preferable, and these buffers are blended in an amount to adjust the pH to the above range. Furthermore, such acids can also be used in combination with alkali metal hydroxides, in particular sodium hydroxide, to form buffer systems.
The liquid oral preparation of the present invention may contain other effective components than the swertia herb extract, and the effective components may be those acting on the digestive system, and examples of the effective components include anise fruit, aloe, fennel, turmeric, lindera root, plectranthus, scutellaria, phellodendron bark, coptidis japonica, processed garlic, curcuma zedoary, ageratum, ramie root, goose skin, poncirus trifoliate, immature bitter orange, cinnamon bark, gentian, red ginseng, magnolia bark, evodia fruit, pepper, african tetrandra, curdlan, zanthoxylum, kaempferia galangal, perilla, amomum shreddatum, dried ginger, cardamom, green tangerine peel, pholidota herb, atractylis lancea, perilla leaf, anise, rhubarb, panax japonicus, clove, dried orange peel, capsicum, lime, animal gall, quassia, nutmeg, ginseng, mint, long pepper, atractylodes rhizome, hop, nux vomica, sleeping leaf, yunna, alpinia oxyphylla, costus, galangal fruit, and the like, Stomach invigorating crude drug extract such as Japanese gentian and rhizoma Alpiniae Officinarum; stomachic agents such as betaine hydrochloride, glutamic acid hydrochloride, carnitine chloride, bethanechol chloride, and dried yeast; antacids such as dried aluminum hydroxide gel, magnesium silicate aluminate, magnesium silicate, synthetic aluminum magnesium carbonate, magnesium oxide, aluminum magnesium hydroxide, aluminum hydroxide gel, aluminum hydroxide-sodium bicarbonate coprecipitate product, aluminum hydroxide-magnesium carbonate mixed dried gel, aluminum hydroxide-magnesium carbonate-silicon carbonate coprecipitate product, magnesium hydroxide, sodium bicarbonate, magnesium carbonate, precipitated calcium carbonate, magnesium metasilicate aluminate, anhydrous calcium hydrogen phosphate, cuttle bone, concha haliotidis, oyster shell, glycine, dihydroxyaluminum aminoacetate salt, and scopolia extract; digestants such as starch digestive enzyme, protein digestive enzyme, fat digestive enzyme, cellulose digestive enzyme, ursodeoxycholic acid, oxycholate, cholic acid, bile powder, bile extract (powder), dehydrocholic acid, and animal gallbladder; intestine regulating agent such as red cedar bud, Catechu, mume fructus, semen Cassiae, and herba Erodii Nepalensis; an antidiarrheal agent such as rivanol, berberine chloride, guaiacol, creosote, phenyl salicylate, guaiacol carbonate, berberine tannate, bismuth subsalicylate, bismuth subnitrate, bismuth subcarbonate, bismuth subgallate, tannic acid, albumin tannate, methylene thymol tannate, kaolin, natural aluminum silicate, aluminum hydroxynaphthoate, pectin, medicinal carbon, precipitated calcium carbonate, calcium lactate, calcium hydrogen phosphate, catechu, dark plum, phellodendron, Japanese coptis, sophora flavescens, geranium nepalense, gallnut, hawthorn, and bayberry; hydrobenraline hydrochloride, dicyclomine hydrochloride, mesterone hydrochloride, scopolamine bromate, methyl atropine bromide, methyl octyl tropine bromide, scopolamine methobromide, methyl 1-ranolazine bromide, methyl benactyzine bromide, belladonna extract, iprodione iodide, diphenyl piperidyl methyl dioxolane hyoscyamine iodide extract, scopine root total alkaloid citrate, papaverine hydrochloride, ethyl aminobenzoate, corydalis tuber, licorice, magnolia cortex, peony and other analgesic and antispasmodic medicines; sodium glycyrrhizate, sodium sulfocellulose, aluminum allantoinate, glycyrrhizic acid and its salts, Glycyrrhrizae radix extract, L-glutamic acid, copper potassium chlorophyll, copper sodium chlorophyll, histidine hydrochloride, pig stomach wall pepsin decomposition product, pig stomach wall acid hydrolysis product, vitamin U, fructus Sorbi Pohuashanensis, rhizoma corydalis, Glycyrrhrizae radix, etc.
In addition, the liquid oral preparation of the present invention may contain stabilizers such as sodium aspartate, sodium alginate, disodium edetate, sodium sulfite, sodium bisulfite and the like; sorbitol, white sugar and other sweeteners; sodium chloride, L-sodium glutamate, Mel, and apple juice; coloring agents such as caramel; flavoring agent such as L-menthol, peppermint flavor, chicory flavor, etc., and essential oil such as lemon oil, orange oil, spearmint oil, etc.; preservatives such as sodium benzoate and butyl p-hydroxybenzoate; polyoxyethylene hardened castor oil ester, a cosolvent of ethanol, and the like.
The liquid oral preparation of the invention is very useful as a liquid oral gastrointestinal drug, and the dosage is usually 20 to 100ml for one time, preferably 1 to 3 times per day.
Examples
The present invention will be described in more detail with reference to the following examples, which, however, are not intended to limit the scope of the invention.
Examples 1 to 2 and comparative examples 1 and 2
A liquid internal preparation containing swertia japonica Makino extract was prepared by the processes shown in tables 1 and 2, wherein the crude drugs in the tables are shown below.
(1) Swertia Japonica Makino extractive solution (1 ml stock solution equivalent to 1g crude drug, extraction solvent; ethanol water solution)
(2) Ginger extract (1 ml of original liquid is equivalent to 1g of crude drug, extraction solvent is ethanol water solution)
(3) Ginseng extract (1 ml of original liquid is equivalent to 4g of original medicine, extraction solvent is ethanol water solution)
(4) Curcuma rhizome extract (1 ml crude liquid equivalent to 1g crude drug, extraction solvent: ethanol water solution)
(5) Cinnamon oil (volatile oil obtained by steam distillation of cinnamon)
(6) Clove oil (volatile oil obtained by steam distillation of clove)
(7) Oleum Foeniculi (volatile oil obtained by steam distilling oleum Foeniculi)
The amounts indicated in the formulations in tables 1 and 2 refer to the amount of 1 vial of 30ml, and citric acid and sodium hydroxide were used to adjust the pH.
TABLE 1
Composition (I) Example 1 Example 2 Example 3 Example 4 Example 5 Example 6 Example 7
Swertia Japonica Makino extractive solution (ml) 0.05 0.05 0.05 0.05 0.05 0.05 0.05
Ginger extract (ml) - 0.1 0.1 0.1 0.1 - 0.1
Ginseng extract (mg) 50 50 - 50 50 - 50
Turmeric extract (ml) 0.1 0.1 0.1 0.1 0.1 -
Cinnamon oil (mg) - 10 10 - 10 10 10
Clove oil (mg) 2 2 2 2 2
Fennel oil (mg) 2 2 2 2 2 2 -
Carnitine chloride (mg) 120 - - 120 - 120 120
Refined white sugar (mg) 1600 1600 1600 1600 1600 1600 1600
D-sorbitol solution (70% by weight) (mg) 900 900 900 900 900 900 900
Polyoxyalkene hardened Castor oil ester (mg) 100 100 100 100 100 100 100
Sodium benzoate (mg) 20 20 20 20 20 20 20
Caramel (mg) 34 34 34 34 34 34 34
Refined water Proper amount of Proper amount of Proper amount of Proper amount of Proper amount of Proper amount of Proper amount of
Total amount (ml) 30 30 30 30 30 30 30
pH 4.2 4.45 4.7 4.95 5.2 5.45 5.7
TABLE 2
Composition (I) Example 8 Example 9 Example 10 Example 11 Example 12 Comparative example 1 Comparative example 2
Swertia Japonica Makino extractive solution (ml) 0.05 0.05 0.05 0.05 0.05 0.05 0.05
Ginger extract (ml) 0.1 0.1 - 0.1 0.1 0.1 -
Ginseng extract (mg) 50 - 50 50 - 50 50
Turmeric extract (ml) 0.1 0.1 - 0.1 0.1 - 0.1
Cinnamon oil (mg) - 10 10 - 10 10 10
Clove oil (mg) 2 - 2 2 2 - -
Fennel oil (mg) 2 2 2 2 2 2
Carnitine chloride (mg) 120 120 120 120 120
Refined white sugar (mg) 1600 1600 1600 1600 1600 1600 1600
Composition (I) Example 8 Example 9 Example 10 Example 11 Example 12 Comparative example 1 Comparative example 2
D-sorbitol solution (70% by weight) (mg) 900 900 900 900 900 900 900
Polyoxyalkene hardened Castor oil ester (mg) 100 100 100 100 100 100 100
Sodium benzoate (mg) 20 20 20 20 20 20 20
Caramel (mg) 34 34 34 34 34 34 34
Refined water Proper amount of Proper amount of Proper amount of Proper amount of Proper amount of Proper amount of Proper amount of
Total amount (ml) 30 30 30 30 30 30 30
pH 5.95 6.2 6.45 6.7 6.95 3.5 7.2
Stability test over time
After the liquid preparations of examples 1 to 12 and comparative examples 1 and 2 were stored at 70 ℃ for 3 days, the remaining amount of swertiamarin in the preparations was measured by high performance liquid chromatography.
As a result, as shown in Table 3, even under a severe condition of 70 ℃ and at a pH of 4 to 7, swertiamarin in the swertia japonica Makino-containing liquid preparation remained stable, and even under a severe condition of 70 ℃ and at a pH of 4.4 to 6.3, the stable residual rate of swertiamarin was 50% or more, while at a pH of 4.5 to 6.0, the stable residual rate of swertiamarin was 60% or more, and at a pH of 4.8 to 5.8, the stable residual rate of swertiamarin was 70% or more.
TABLE 3
Liquid preparation Residual rate of swertiamarin (%)
Comparative example 1 0
Example 1 25.0
Example 2 52.1
Example 3 63.0
Example 4 74.7
Example 5 81.2
Example 6 81.5
Example 7 75.9
Example 8 68.9
Example 9 55.8
Example 10 41.3
Example 11 31.6
Example 12 12.5
Comparative example 2 8.2
Industrial applicability of the invention
The liquid internal preparation of the present invention can stably maintain the active ingredients of swertia japonica Makino extract for a long period of time, and thus can maintain the drug effect for a long period of time.

Claims (3)

1. A liquid oral preparation comprises swertia Japonica Makino extract, effective component selected from rhizoma Zingiberis recens extract, Ginseng radix extract, Curcuma rhizome extract, oleum Cinnamomi, oleum Caryophylli, oleum Foeniculi or carnitine chloride, and adjuvant component in balance, and has pH of 4-7.
2. The oral liquid preparation according to claim 1, wherein the pH is adjusted to 4.4 to 6.3.
3. The oral liquid preparation according to claim 1 or 2, wherein the auxiliary ingredients are refined white sugar, sorbitol, caramel, sodium benzoate, and polyoxyethylene hardened castor oil.
HK09112032.6A 2001-08-31 2009-12-22 Liquid preparation for internal use HK1132190B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-264442 2001-08-31
JP2001264442A JP2003073291A (en) 2001-08-31 2001-08-31 Oral liquid formulation

Publications (2)

Publication Number Publication Date
HK1132190A1 HK1132190A1 (en) 2010-02-19
HK1132190B true HK1132190B (en) 2011-02-18

Family

ID=

Similar Documents

Publication Publication Date Title
Kaur et al. Herbal medicines: possible risks and benefits
KR0145739B1 (en) Effervescent tablet
CN101254249B (en) A Chinese and Western medicine compound preparation for treating cough with excessive phlegm and production method thereof
WO2024001141A1 (en) Use of herba agastachis stomach-calming prescription in preparation of drug for resisting helicobacter pylori
CN105663014A (en) Inflammation diminishing and whitening toothpaste containing rhizoma coptidis and fresh ginger
HK1053988A1 (en) Liquid preparations for internaluse
US20190160126A1 (en) Compositions and methods for treating reproductive indicators symptomatic of male infertility
CN100518806C (en) Medicinal composition
HK1132190B (en) Liquid preparation for internal use
JP6771274B2 (en) Oral composition
CN101143202A (en) Compound oral administration preparation with protective function to chemical liver injury
CN102106999A (en) Chinese medicinal compound preparation for treating dysphagia due to stroke and preparation method thereof
KR20190068990A (en) Composition for relieving and healing menstrual pain containing fermented Celastrus orbiculatus
JPH02193926A (en) Gastrointestinal drug
RU2157226C2 (en) Anticoughing preparation and method of its preparing
CN105031284A (en) Oral medicament for treatment of oral leukoplakia
CN105031170A (en) Healthcare foot bath powder and preparing method thereof
CN117462642B (en) Traditional Chinese medicine composition for treating diarrhea and preparation method and application thereof
JPH06107553A (en) Composition having analgesic function
CN102872289B (en) Traditional Chinese medicine composite for treating chronic gastritis and preparation method thereof
CN101284069A (en) Chinese herbal medicine lozenge containing Chinese herbal medicine active composition for resisting helicobacter pylori and preparation method thereof
EP0142036A1 (en) Pharmaceutical agent for ulcers of the gastro-intestinal tract
JP2019214622A (en) Oral composition
CN108938785B (en) Traditional Chinese medicine composition for treating cough variant asthma and preparation method thereof
CN105853912A (en) Traditional Chinese medicine composition for treating subacute thyroiditis and preparation method and use thereof